BOC Sciences

    Country: Country United States

    Business Type: Trading Company

    Premium supplierPremium
    supplier

  • Ms.Linna Green
    Tel: 1-631-485-4226

  • Mobile:
  • Tel:1-631-485-4226
  • Fax:1-631-614-7828
  • URL:https://www.bocsci.com/
  • Province/state:New York
  • City:Shirley
  • Street:Ramsey Road
  • MaxCard:
Home > Products >  Quizartinib

Quizartinib CAS NO.950769-58-1

  • Min.Order: 1 Gram
  • Payment Terms: L/C
  • Product Details

Keywords

  • 950769-58-1
  • AC220
  • Quizartinib

Quick Details

  • ProName: Quizartinib
  • CasNo: 950769-58-1
  • Appearance: White to off-white solid
  • Application: research use
  • DeliveryTime: 7 days
  • PackAge: inquiry
  • Port: inquiry
  • ProductionCapacity: 10 Kilogram/Month
  • Purity: >98%
  • Transportation: inquiry
  • LimitNum: 1 Gram

Superiority

BOC Sciences is committed to supplying cost-effective products and services. We provide Quizartinib (Cas:950769-58-1). Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.More information please visit the website: #

Details

BOC Sciences is committed to supplying cost-effective products and services. We provide Quizartinib (Cas:950769-58-1). Quizartinib is an orally available small molecule with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.More information please visit the website: #

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog